260 related articles for article (PubMed ID: 29486959)
1. Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients.
Lappin JM; Wijaya M; Watkins A; Morell R; Teasdale S; Lederman O; Rosenbaum S; Dick S; Ward P; Curtis J
Schizophr Res; 2018 Sep; 199():367-373. PubMed ID: 29486959
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?
Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM
Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650
[TBL] [Abstract][Full Text] [Related]
3. Metabolic monitoring and management among clozapine users.
Tso G; Kumar P; Jayasooriya T; Kisely S; Siskind D
Australas Psychiatry; 2017 Feb; 25(1):48-52. PubMed ID: 27590080
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.
Brunero S; Lamont S; Fairbrother G
Arch Psychiatr Nurs; 2009 Jun; 23(3):261-8. PubMed ID: 19446781
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of the metabolic syndrome among patients receiving clozapine.
Lamberti JS; Olson D; Crilly JF; Olivares T; Williams GC; Tu X; Tang W; Wiener K; Dvorin S; Dietz MB
Am J Psychiatry; 2006 Jul; 163(7):1273-6. PubMed ID: 16816234
[TBL] [Abstract][Full Text] [Related]
6. Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.
Siskind DJ; Harris M; Phillipou A; Morgan VA; Waterreus A; Galletly C; Carr VJ; Harvey C; Castle D
Epidemiol Psychiatr Sci; 2017 Jun; 26(3):325-337. PubMed ID: 27426892
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics.
Krane-Gartiser K; Breum L; Glümrr C; Linneberg A; Madsen M; Køster A; Jepsen PW; Fink-Jensen A
Nord J Psychiatry; 2011 Oct; 65(5):345-52. PubMed ID: 21428861
[TBL] [Abstract][Full Text] [Related]
8. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates.
Lamberti JS; Costea GO; Olson D; Crilly JF; Maharaj K; Tu X; Groman A; Dietz MB; Bushey MP; Olivares T; Wiener K
J Clin Psychiatry; 2005 Jul; 66(7):900-6. PubMed ID: 16013906
[TBL] [Abstract][Full Text] [Related]
9. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia.
Eskelinen S; Sailas E; Joutsenniemi K; Holi M; Suvisaari J
Nord J Psychiatry; 2015 Jul; 69(5):339-45. PubMed ID: 25981178
[TBL] [Abstract][Full Text] [Related]
10. Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital.
Stone-Brown K; Naji M; Francioni A; Myers K; Samarendra H; Mushtaq-Chaudhry H; Heslop S; Sengupta S; Ross CC; Larkin F; Das M
CNS Spectr; 2016 Feb; 21(1):60-9. PubMed ID: 26726766
[TBL] [Abstract][Full Text] [Related]
11. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
12. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database.
Sicras-Mainar A; Blanca-Tamayo M; Rejas-Gutiérrez J; Navarro-Artieda R
Eur Psychiatry; 2008 Mar; 23(2):100-8. PubMed ID: 17904825
[TBL] [Abstract][Full Text] [Related]
13. Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.
Bressington D; Mui J; Tse ML; Gray R; Cheung EF; Chien WT
BMC Psychiatry; 2016 Nov; 16(1):411. PubMed ID: 27863522
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and associations of the metabolic syndrome among patients prescribed clozapine.
Ahmed M; Hussain I; O'Brien SM; Dineen B; Griffin D; McDonald C
Ir J Med Sci; 2008 Sep; 177(3):205-10. PubMed ID: 18461270
[TBL] [Abstract][Full Text] [Related]
15. Genetic Determinants of Clozapine-Induced Metabolic Side Effects.
Vasudev K; Choi YH; Norman R; Kim RB; Schwarz UI
Can J Psychiatry; 2017 Feb; 62(2):138-149. PubMed ID: 27681143
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Chart Review of Screening on the Prevalence of Metabolic Syndrome (MetS) in an Irish Community Mental Health Service.
Cocoman AM; Gallagher D
Issues Ment Health Nurs; 2019 Oct; 40(10):895-901. PubMed ID: 31295053
[TBL] [Abstract][Full Text] [Related]
17. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
18. Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication.
Morell R; Curtis J; Watkins A; Poole J; Fibbins H; Rossimel E; Gerrard M; White A; Teasdale S; Ward PB; Lappin J
Psychiatry Res; 2019 Nov; 281():112606. PubMed ID: 31629301
[TBL] [Abstract][Full Text] [Related]
19. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.
Kelly AC; Sheitman BB; Hamer RM; Rhyne DC; Reed RM; Graham KA; Rau SW; Gilmore JH; Perkins DO; Peebles SS; VanderZwaag CJ; Jarskog LF
J Clin Psychopharmacol; 2014 Aug; 34(4):441-5. PubMed ID: 24943389
[TBL] [Abstract][Full Text] [Related]
20. Determining rates of hepatitis C in a clozapine treated cohort.
Sockalingam S; Shammi C; Powell V; Barker L; Remington G
Schizophr Res; 2010 Dec; 124(1-3):86-90. PubMed ID: 20605572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
